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Background: A significant amount of common variable immunodeficiency (CVID) 
patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) 
is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment 
option for both, CVID and AITP. Nonetheless, due to fewer systemic side effects, immu-
noglobulins are increasingly applied subcutaneously (SCIG).
Objective: To compare the efficacy and safety of IVIG and SCIG treatment in patients 
with both CVID and clinical relevant thrombocytopenia in the prevention of AITP bouts.
Methods: Patients with both CVID and AITP were enrolled at the Centre for Chronic 
Immunodeficiency in Freiburg, Germany and at the Royal Free Hospital, London, UK. 
Clinical and laboratory features of patients were collected and analyzed.
results: This retrospective study recruited 61 adult patients between 19 and 71 years 
of age who had a diagnosis of CVID and at least one bout of thrombocytopenia defined 
as a platelet count of <50,000/μl if bleeding episodes occurred, or a platelet count of 
<20,000/μl without bleeding. Thirty patients received immunoglobulin through IVIG, and 
31 patients were on SCIG replacement. One patient of the IVIG-group was excluded, 
because of a diffuse large B-cell lymphoma. We did not find a higher occurrence of 
thrombocytopenic events in CVID patients who received SCIG, compared to CVID 
patients who had IVIG, but we identified a low IgG through level as a risk factor for AITP 
bouts.
conclusion: SCIG is at least as safe as IVIG for patients with CVID and concomitant 
AITP. However, an IgG through level under 7 g/l is a key factor for the development 
of AITP.
Keywords: common variable immunodeficiency, autoimmune thrombocytopenia, intravenous immunoglobulin, 
subcutaneous immunoglobulin, immunoglobulin replacement therapy
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inTrODUcTiOn
Common variable immunodeficiency (CVID) is the most preva­
lent symptomatic primary immunodeficiency (1). It is character­
ized by hypogammaglobulinemia and an impaired antibody 
response leading to recurrent and chronic infections (2). On the 
other hand, a significant amount of patients manifest with auto­
immunity. Specifically, autoimmune thrombocytopenia (AITP) 
is commonly seen in patients with CVID with an incidence of up 
to 14% (3, 4). Intravenous immunoglobulin (IVIG) is being used 
as a replacement therapy [immunoglobulin replacement therapy 
(IGRT)] for CVID. However, IVIG can also be used at high doses 
for the treatment of AITP. It is thought that maintenance IGRT 
might reduce or even prevent recurrent bouts of AITP. Currently, 
immunoglobulins are increasingly applied subcutaneously in 
patients with CVID, as there are fewer systemic side effects com­
pared to intravenous applications and it seems to improve the 
patients’ quality of life (5, 6).
Therefore, the objective of this study was to answer the ques­
tion: Is it safe to switch patients with CVID and AITP from IVIG 
to subcutaneous immunoglobulin (SCIG) treatment, with respect 
to the prevention of clinically relevant thrombocytopenia?
MaTerials anD MeThODs
Patients with both CVID, based on the European Society for 
Immunodeficiencies criteria, and clinically relevant AITP were 
included in this cohort study. This retrospective study covered 
5 years of chart reviews between 2011 and 2015. Patients were 
recruited at the Center for Chronic Immunodeficiency in 
Freiburg, Germany and at the Royal Free Hospital, London, UK. 
Information on immunological findings, clinical manifestations, 
and immunoglobulin replacement therapy was collected.
The primary study endpoint was a severe thrombocytopenic 
event, defined as a platelet count of <50,000/μl if bleeding episodes 
occurred, or a platelet count of <20,000/μl without bleeding. To 
investigate the incidence of thrombocytopenic events in each 
group (IVIG vs. SCIG), we retrospectively reviewed participants’ 
platelet counts over a period of 5 years.
We estimated the frequency of thrombocytopenic events by 
summing up all 6­month periods, in which patients had at least 
one documented thrombocytopenic event, since the majority of 
participants had a routine blood draw every 6 months and addi­
tionally when bleeding events (including petechial) occurred.
Differences between groups were analyzed using the non­
parametric Chi­square test and Mann–Whitney U­test. Results 
are illustrated using bar charts or box plot diagrams; with boxes 
representing the lower quartile, the median and the upper 
quartile, while the whiskers show the 10th and 90th percentiles. 
A Kaplan–Meier analysis was performed to evaluate the occurrence 
of primary study endpoint. The Kaplan–Meier curves were com­
pared using log­rank test. Data were analyzed using GraphPad 
Prism version 7.01 (GraphPad Software, USA). p <  0.05 was 
considered significant.
Written consent was obtained of all patients. This retrospective 
study was performed in accordance with the ethical stand ards of the 
Helsinki declaration and was approved by the institutional review 
boards of the two hospitals. Ethics protocol No. 295/13 from the 
University Hospital of the Albert Ludwigs University, Freiburg; 
and No. 04/Q0501/119 for the Royal Free Hospital, Univer­
sity College London, Institute of Immunity and Transplantation, 
London, UK.
resUlTs
This retrospective cohort study recruited 61 adult patients bet ween 
19 and 71 years of age who had a diagnosis of CVID and at least 
one event of clinical significant thrombocytopenia at any time 
during their medical history. Forty­two patients were enrolled at 
the Center for Chronic Immunodeficiency in Freiburg, Germany, 
and 19 patients were recruited at the Royal Free Hospital in 
London, UK. All participants were on a stable dose of IgG replace­
ment (there was no more variation than 10%), with a median of 
477.5 mg/kg/month (range: 232–942), and a target trough level 
of >7g/l. Thirty patients received immunoglobulin through the 
intravenous route (IVIG), and 31 patients were on subcutaneous 
immunoglobulin (SCIG) replacement.
Two patients changed from IVIG to SCIG during the obser­
vation period. They were documented in the IVIG cohort until 
the date of switching and included in the SCIG cohort 3 months 
after switching from IVIG to SCIG. No patient switched from 
SCIG to IVIG. Participants had platelet counts and IgG trough 
levels determined at least every 6­month, and additionally during 
bleeding episodes (Table 1). Trough levels used for the analysis 
represent the average level among measurements.
Reviewing the patients’platelet counts and patient­charts over 
the last 5 years, we counted eight patients in the SCIG­group, and 
eight patients in the IVIG­group, which were affected by throm­
bocytopenic events. However, one patient of the IVIG­group had 
to be excluded, since his thrombocytopenic events were directly 
related to chemotherapy he had been receiving because of a dif­
fuse large B­cell lymphoma. All other thrombocytopenic events 
were classified as AITP.
Patients with AITP under IVIG substitution had infusions 
scheduled every four weeks; five of them had about of AITP dur­
ing the third week after infusion. SCIG patients with AITP had 
their infusions scheduled as follows: six patients had one infusion 
per week; one patient had injections three times a week, and one 
individual had infusions every 10 days.
There were no statistically significant correlations between 
gender (p = 0.3248) and thrombocytopenic events. When com­
paring Ig replacement, there were no significant differences in the 
occurrence of thrombocytopenia between the IVIG and SCIG­
group (Figure 1). We, therefore, concluded that CVID patients 
who received subcutaneously immunoglobulin treatment were 
not more susceptible to recurrent thrombocytopenic events than 
CVID patients on IVIG substitution. Moreover, we excluded 
steroid treatment and splenectomy as confounding factors as we 
did not observe a significant difference when comparing AITP 
patients on IVIG or SCIG (Figures 2A,B).
Comparing IgG trough levels, we again found no differ­
ence between patients in the IVIG­group and the SCIG­group 
(p =  0.4634) (Figure  3). But those who were affected by a 
thrombocytopenic event had a higher relative frequency of IgG 
TaBle 1 | Patient demographics and disease characteristics.
iD age 
range
igg 
replacement
igg dose 
(g/month)
igg levela 
(g/l)
Median thrombocytes 
(Tsd/μl)
immunomodulation Other disorders
1 36–40 IV 20 9.83 312 No Splenomegaly
2 46–50 IV 90 10.9 189 Rituximab Splenomegaly, AIN
3 31–35 IV 120 10.5 151 Rituximab Splenomegaly
4 51–55 IV 25 15.8 25 No Splenectomy, lymphoma
5 21–25 SC 25 3.9 25 No Splenomegaly
6 21–25 IV 20 4.3 211 Steroids Splenomegaly, AIN
7 51–55 IV 20 8.2 134 Steroids Splenomegaly
8 51–55 SC 20 8.8 200 No Splenomegaly
9 21–25 IV 20 5.7 25.6 Steroids Splenectomy
10 51–55 SC 25 8.8 45.1 Steroids None
11 36–40 IV 20 8 145 No Splenectomy
12 41–45 SC 32 6.1 250 Steroids Splenomegaly
13 51–55 SC 45 10 107 Steroids Splenomegaly
14 51–55 SC 33 7.0 140 Steroids Splenomegaly
15 56–60 SC 20 5.1 136 No Splenomegaly
16 51–55 SC 64 8.7 257 No Splenomegaly
17 41–45 SC 30 9.2 158 Steroids Splenomegaly
18 36–40 SC 25 9.8 181 No Psoriasis
19 26–30 SC 28 7.5 28 Steroids Splenomegaly
20 51–55 IV 20 9.8 20 Methotrexate, 
steroids
Splenomegaly, rheumatoid arthritis, 
antiphospholipid syndrome
21 51–55 SC 50 9.4 147 Rituximab Splenomegaly
22 41–45 SC 38 7.8 38 Steroids Splenomegaly
23 26–30 IV 45 15.6 97 Steroids Splenomegaly
24 46–50 SC 51 10.9 60 Steroids Splenomegaly
25 46–50 SC 30 6.1 300 No Splenectomy
26 41–45 SC 64 8.4 75 No Splenomegaly
27 61–65 SC 20 8.7 20 No Splenomegaly
28 51–55 IV 38 11.2 38 No Splenomegaly
29 41–45 SC 38 9.4 114 Steroids, ciclosporin Splenomegaly, autoimmune enteropathy, vitiligo
30 21–25 SC 35 8.1 205 No Splenomegaly
31 36–40 SC 20 8.7 12.8 No None
32 21–25 SC 40 7.0 126 No Splenomegaly
33 31–35 IV 20 9.6 175 No Splenectomy
34 61–65 SC 36 9.5 36 Rituximab Splenomegaly
35 41–45 SC 40 12.0 170 Steroids Splenomegaly
36 56–60 IV 28 9.8 177 No Celiac disease
37 36–40 SC 53 7.1 84 Rituximab Splenomegaly
38 21–25 IV 20 5.9 80 No Splenectomy
39 26–30 IV 20 10.6 152 No Splenomegaly
40 31–35 IV 20 8.7 20 No Splenomegaly
41 66–70 IV 25 10.8 160 No Splenomegaly
42 26–30 SC 20 6.4 20 No Splenomegaly
43 36–40 SC 30 12.7 220 Rituximab Splenectomy
44 61–65 IV 40 9.8 305 No None
45 46–50 IV 30 8.4 220 No None
46 51–55 IV 50 8.8 146 Rituximab AIHA
47 31–35 SC 40 8.2 175 No None
48 31–35 IV 30 13.5 158 Rituximab AIN
49 21–25 IV 35 8.0 442 Rituximab Splenectomy
50 61–65 IV 40 14.8 253 No Splenectomy
51 36–40 SC 30 9.4 182 No None
52 71–75 IV 30 13 11.2 Rituximab Splenectomy
53 36–40 IV 35 5.2 141 No None
54 46–50 IV 40 11.2 132 Rituximab None
55 51–55 IV 30 7.9 8.6 No None
56 51–55 SC 20 11.2 308 No None
57 31–35 IV 30 16.3 169 No None
58 41–45 IV 30 7.9 131 No None
59 36–40 SC 30 8.6 233 No Splenectomy
60 16–20 SC 30 10.2 150 No None
61 56–60 IV 25 10.7 253 No Splenectomy
IV, intravenous; SC, subcutaneous; AIHA, autoimmune hemolytic anemia; AIN, autoimmune neutropenia.
aIgG levels under replacement therapy.
Bold numbers indicate patients with autoimmune thrombocytopenia.
3
Scheuerlein et al. Immunoglobulin Therapy CVID and AITP
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1656
FigUre 2 | Comparison between immunoglobulin replacement therapy 
(IGRT) and potential confounding factors in the occurrence of autoimmune 
thrombocytopenia (AITP) bouts. Data are expressed as the number of 
patients with AITP bouts receiving IGRT (the total is 14). Chi-squared was 
used. (a) No difference was observed when comparing patients receiving 
steroids or other immunomodulatory treatment p = 0.5692. (B) Status of 
splenectomy made no difference in the occurrence of thrombocytopenic 
events p = 0.0769.
FigUre 1 | Common variable immunodeficiency (CVID) patients with 
autoimmune thrombocytopenia on replacement therapy. Kaplan–Meier  
curves showing the occurrence of thrombocytopenic events in patients 
receiving subcutaneous immunoglobulin (SCIG) and intravenous 
immunoglobulin (IVIG). Log-rank test was used to analyze difference  
between groups. No differences were observed (p = 0.528).
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FigUre 3 | Replacement therapy among autoimmune thrombocytopenia 
(AITP) patients related to IgG through levels. Number of patients with AITP 
bouts under intravenous immunoglobulin (IVIG) (n = 7) and under SCIG 
(n = 8). Box plot diagrams represent the lower quartile, the median and the 
upper quartile, while the whiskers show the 10th and 90th percentiles. 
Differences were compared by the Mann–Whitney U-test. No differences 
were observed, p = 0.4634. p is considered significant when < 0.05.
FigUre 4 | Occurrence of autoimmune thrombocytopenia (AITP) related to 
IgG through levels. Patients with AITP (n = 15) and those without bouts 
(n = 45) are depicted in box plot diagrams. Box plots show the lower quartile, 
the median and the upper quartile, while the whiskers show the 10th and 
90th percentiles. A significant difference was observed among patients with 
through levels under 7 g/l. From the AITP group 12 patients (80%) had 
through levels below this cut point, while from the non-AITP group 44 
patients (97.7%) where above 7 g/l. Group comparisons were performed  
by the Mann–Whitney U test. p is considered significant when <0.05.
DiscUssiOn
Given that IGRT is increasingly applied subcutaneously; we 
expected that this study could help to understand better the role 
of available options of IGRT in patients with both AITP and 
CVID in a clinical setting. The German Registry for PID found 
trough­level under 7 g/l in serum compared to patients without a 
thrombocytopenic event (OR 0.75, 95% CI 0.12–7.03; p < 0.0001) 
(Figure 4). This indicates that a low IgG level is a key factor for 
the development of thrombocytopenia. In addition, there was no 
patient affected by autoimmune hemolytic anemia or autoim­
mune neutropenia during the 5­year observation period.
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In summary, we did not find a higher occurrence of thrombo­
cytopenic events in CVID patients who received SCIG, compared 
to CVID patients who had an intravenous application of IgG, 
but we identified a low IgG through level as a risk factor for ITP 
bouts.
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This retrospective study was performed in accordance with the 
ethical standards of the Helsinki declaration and was approved 
by the institutional review boards of the two hospitals. Ethics 
protocol No. 295/13 from the University Hospital of the Albert 
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Royal Free Hospital, University College London, Institute of 
Immunity and Transplantation, London, UK.
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out that 73% of patients with PID are receiving SCIG and 27% are 
under IVIG replacement (7).
In this cohort study, the groups differed at baseline in partici­
pant characteristics: gender, splenectomy status, immunomodu­
lation, and replacement therapy. The comparability of the groups 
was questioned by counting the occurrence of influencing factors. 
We found no statistically significant differences related to gender. 
Therapeutic options for AITP include steroids, immunosuppres­
sant, and splenectomy (8, 9). However, none of these factors seem 
to have influenced the IGRT administration route.
Antibodies to thrombocytes were not tested for all patients; the 
measurement of platelet­associated IgG for the diagnosis of ITP 
is published to have a sensitivity around 90%, but its specificity is 
only 27%; hence, the positive predictive value is only <50% and 
its diagnostic value is poor. While the measurement of specific 
platelet glycoprotein antibodies has higher specificity (78–92%), 
its diagnostic value is limited by low sensitivity (49–66%) with 
a positive predictive value of 80–83% (10). We differentiated 
hypersplenism from AITP according to the clinical observation 
of the platelets kinetics: in AITP the drop of platelets is quick, 
while hypersplenism develops more slowly in CVID and usually 
leads to a gradual reduction in platelet counts.
When comparing IVIG vs. SCIG replacement with the occur­
rence of AITP events, we did not find a different incidence of 
thrombocytopenic events between groups. Although our sample 
size is limited, our data do not give a signal that SCIG is less safe 
than IVIG for patients with CVID and concomitant autoimmune 
cytopenia.
It has been established that target through serum IgG, achi­
eved by either intravenous or subcutaneous route varies and the 
goal is to prevent infections (1, 11).
Trough levels have not been previously related to thrombocy­
topenic events. Our study suggests IgG trough­levels under 7 g/l 
point to be a key factor for development of thrombocytopenia.
This study is limited by its statistical power and its retrospec­
tive design. Based on statistical tests we analyzed differences 
between groups and, therefore, only controlled for type I errors. 
Due to the limited sample size there is possibly a high risk 
of type II errors, for which our tests did not control. Hence, 
further investigations are necessary. This should be addressed 
in the coming years by collecting prospective data on the above 
identified 60 patients.
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